-+ 0.00%
-+ 0.00%
-+ 0.00%

Guggenheim Maintains Buy on Rhythm Pharmaceuticals, Raises Price Target to $140

Benzinga·12/17/2025 12:54:56
Listen to the news
Guggenheim analyst Seamus Fernandez maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Buy and raises the price target from $120 to $140.